NEW YORK – With its web-based digital pathology platform, Tribun Health said that its whole-slide image management software offers labs workflow improvements with the ability to integrate its system ...

The firm is also considering a US regulatory submission of its QiAcuityDx system along with a companion diagnostic test.

The test uses machine learning to analyze biomarkers and clinical features to determine prostate cancer aggressiveness.

NEW YORK – With new data and plans for additional clinical validation in the works, liquid biopsy firm PanGia Biotech is making strides toward commercialization of its urine-based prostate cancer ...

The company plans to bring to market in the coming years a series of microarray-based tests for autoimmune diseases and allergies, among other tests.

The ruling ensures continued coverage, without patient cost-sharing, of services including BRCA testing and colorectal cancer screening, potentially impacting firms like Exact Sciences.

The ASM partnered with the US Centers for Disease Control and Prevention on the guidance published this month in Clinical Microbiology Reviews.

The Helsinki-based firm's test is used to automate breast cancer grading using AI-developed models, and it is integrated into the firm's breast cancer suite.

NEW YORK — Gut microbiome health startup 32 Biosciences said Tuesday that it has raised $6 million in private funding, which it said will support the development of its first products. 32 Biosciences ...

The company has reduced the turnaround time to a little over 48 hours for its pathogen-agnostic metagenomic next-generation sequencing test service for CNS infections ...

NEW YORK – Quest Diagnostics believes a proteomic blood test could help identify patients at high risk of certain cancers who could benefit from conventional screening approaches or other evaluations.

NEW YORK – Quest Diagnostics said Tuesday that it is collaborating with the University of Texas MD Anderson Cancer Center to develop and validate a laboratory-developed test to identify individuals ...